Tag Archives: Loss

The BMS-Celgene merger’s Achilles heel? An earlier-than-expected Revlimid patent loss

Executives from Bristol-Myers Squibb and Celgene were just a few minutes into a Q&A with investors about their newly announced $ 74 billion merger when longtime biotech analyst Tim Anderson raised a troubling question. One of Celgene’s crown jewels, the $ 8-billion-per-year multiple myeloma drug Revlimid, is facing patent challenges that could open it up to earlier-than-expected generic… Read More »